Small interfering RNAs (siRNA) were designed to target the bcr-abl oncogene which causes chronic myeloid and bcr-abl positive acute lymphoblastic leukemia (CML, ALL). Chemically synthesized anti-bcr-abl siRNAs were selected using reporter gene constructs and were found to reduce bcr-abl mRNA up to 87% in bcrabl positive cell lines and in primary cells from CML patients. This mRNA reduction was specific for bcr-abl since both c-abl and c-bcr mRNA levels remained unaffected.
Introduction
RNA interference (RNAi) describes a highly conserved regulatory mechanism that mediates sequence-specific post-transcriptional gene silencing initiated by double-stranded RNA (dsRNA) (1) (2) (3) . The RNAse III enzyme Dicer processes dsRNA into ~22 nucleotides (nt) small interfering RNAs (siRNA) (4) which serve as guide sequences to induce target-specific mRNA cleavage by the RNA-induced silencing complex RISC (5) . In plants and C. elegans, RNAi may involve the amplification of dsRNA by a RNA-dependent RNA polymerase (RdRP) (6) and enables systemic, long -term, and heritable gene silencing. In contrast, RNAi in Drosophila and mammals seems cell autonomous, transient and non-heritable. Since exogenous application of siRNAs can efficiently trigger RNAi in mammalian cells (7, 8) , siRNAs For personal use only. on October 31, 2017. by guest www.bloodjournal.org From are increasingly used in transient (co)transfection assays to modulate gene expression in mammalian including human cells (9) (10) (11) (12) .
Fusion-transcripts encoding oncogenic proteins may represent potential targets for a tumor-specific RNAi-approach. The Philadelphia (Ph-) translocation t(9;22)(q34;q11) generates the bcr-abl fusion gene characteristic for chronic myelogenous leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) (13) .
Bcr-abl encodes a constitutively active cytoplasmic tyrosine kinase that is both necessary and sufficient to induce and maintain leukemic transformation (14) (15) (16) .
We demonstrate that anti-bcr-abl siRNAs specifically inhibit bcr-abl mRNA expression in hematopoietic cell lines and primary CML cells. They reduce BCR-ABL protein expression and inhibit BCR-ABL -, but not cytokine-dependent cell proliferation. Therefore, anti-bcr-abl siRNAs may allow further analysis of BCR-ABL functions, and, eventually, may lead to RNAi-based therapeutics.
Material and Methods

siRNAs
21-nt single-stranded RNAs directed against the fusion sequence of bcr-abl were chemically synthesized (BioSpring, Frankfurt, Germany)( Figure 1A ). The sense and antisense sequences were b3a2_1: 5'-GCAGAGUUCAAAAGCCCUUdTdT-3', b3a2_3:
5'-AGCAGAGUUCAAAAGCCCUdTdT-3', and b3a2_1: 5'-AAGGGCUUUUGAACUCUGCdTdT-3', b3a2_3: 5'-AGGGCUUUUGAACUCUGCUdTdT-3', respectively. Control anti-GL2_ and invGL2_siRNAs targeting GL2-luciferase, anti-laminA/C siRNAs, and siRNA-duplexes were generated as described by Elbashir et al. (7) . 
Real-time RT-PCR
Real-time Taqman 
Immunoblotting and immunofluorescence microscopy
Cellular lysates from TonB cells were immunoblotted with polyclonal anti-bcr antibody (N-20) and polyclonal anti-Stat5 antibody (C-17) as described (18) . To quantify transduction efficacy, laminA/C immunostaining was performed using a monoclonal anti-laminA/C antibody (sc-6215, all antibodies from Santa Cruz Biotechnology) as described (7).
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Primary normal and CML cells
Normal and CML CD34+ cells were purified to > 95% as described (19). Primary CD34+ or peripheral blood derived mononuclear cells (PBMNC) cells were cultured in X-VIVO/1% HSA with recombinant human SCF (100 ng/ml), Flt-3-ligand (100 ng/ml), and TPO (20 ng/ml) before electroporation, and GM-CSF and IL-3 (10 ng/ml each) were added thereafter. Methylcellulose colony assays were performed as described (19).
Results and Discussion
Selection of anti-bcr-abl siRNAs
Efficient siRNAs targeted against the b3a2-fusion sequence of bcr-abl were selected by cotransfection with a chimeric bcr-abl-EGFP reporter gene in HeLa cells.
Hela cells could be transfected up to 95% (data not shown). Out of four chemically
synthesized 21-nt siRNAs tested, b3a2_1 and b3a2_3 ( Figure 1A) were the most efficient siRNAs. They reduced the number of fluorescent cells (up to 90%), bcr-abl-EGFP mRNA levels (up to 87%), and the fluorescence intensity per cell (up to onehundred-fold) 24 hours after transfection (data not shown). RNAi was specific since no reduction in fluorescence intensity was found with control siRNAs or when native EGFP without bcr-abl sequences was used as reporter. Furthermore, anti b3a2-bcrabl siRNA only reduced the b3a2-, but not the b2a2-variant of a bcr-abl-EGFP reporter gene and vice versa (data not shown).
Effects of siRNAs in hematopoietic cell lines
b3a2_1 and b3a2_3 siRNAs were tested in Ph+ K562 and TonB cells expressing bcr-abl under control of a doxycycline inducible promoter (17) .
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Transfection efficacy was analysed using the laminA/C system and reached about 80% in K562 cells (data not shown). b3a2_1 and b3a2_3, but not control siRNAs, reduced bcr-abl mRNA levels after 24 and 48 hours up to 24.8% and 35.2% (b3a2_1), and 32.4% and 61% (b3a2_3), respectively (Table 1 and data not shown).
Notably, c-bcr and c-abl mRNA levels remained unaffected demonstrating the specificity of anti-bcr-abl siRNAs (Table 1) Figure 1D,E) . Again, cultures of TonB cells treated with b3a2_1 resumed growth after 3 to 5 days in all conditions tested. In parental bcr-ablnegative BaF3 cells siRNA had no effect on cell proliferation (data not shown).
siRNA activity in primary hematopoietic cells
siRNA efficacy in primary hematopoietic cells was first demonstrated in normal CD34+ cells using the laminA/C system. Anti-laminA/C siRNA reduced laminA/C protein expression by about 70% ( Figure 1F ). Next, electroporation of PBMNC or purified CD34+ from six CML patients with b3a2_1 siRNA reduced bcr-abl-mRNA levels by 50% to 79% in comparison to control siRNA (100%) ( Table 1) . Again, c-bcr Table 1 and data not shown). Table 1 Effects of anti-bcr-abl siRNAs on bcr-abl mRNA expression and colony formation of primary CML cells
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